SPRO.US Spero Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.8997 USD
Close of Nov 17, 2026
0.8800 3.08
Market cap
USD 52.4M
P/E
-
P/B
74.39x
ROE
-10,419.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SPRO.US undervalued?

Graham number

The Graham number of Spero Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spero Therapeutics Inc fundamental analysis

No fundamental analysis for Spero Therapeutics Inc yet.

Spero Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It …

Full company profile